RecruitingRelapsed Adult AMLPrimary Refractory Acute Myeloid LeukemiaHigh Risk Acute Myeloid Leukemia

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Eligible age

18–120 yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Sponsor: Massachusetts General Hospital

You may qualify if…

✓ Patient Inclusion Criteria
✓ Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
✓ Patients with new diagnosis ≥ 60 years of age
✓ An antecedent hematologic disorder
✓ Therapy related-disease
✓ Relapsed or primary refractory AML
✓ Within five business days of initiating therapy with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial.
✓ Caregiver Inclusion Criteria

You may not qualify if…

✕ \- Patient Exclusion Criteria
✕ Patients with a diagnosis of acute promyelocytic leukemia (APML)
✕ Patients with AML receiving supportive care alone
✕ Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
✕ Patients seen by a palliative care clinician (MD, DO, APP) during two previous hospitalizations in the six months prior to enrollment
✕ Patients expected to be discharged within 2 days